Paper: Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research Vania Hungria, MD, PhD 1, Pawel Robak, MD, PhD 2 *, Marek Hus, MD, PhD 3 *, Vera Zherebtsova, MD 4 *, Christopher Ward, MD, PhD 5 *, Phoebe Joy Ho, MBBS 6, Roman Hajek, MD, PhD 7, Kihyun Kim, MD 8 *, Sebastian Grosicki, MD, PhD 9 *, Hanlon Sia, MBBS FRACP FRCPA
